Johnson & Johnson has reported poor US sales for its first quarter, but the overall result is boosted by a stronger overseas performance and currency translations.
France-based pharmaceutical group Sanofi-aventis has increased its presence in the US market and expanded into personal care with the acquisition of Chattem.
The approval of an eyelash enhancing prescription drug from Allergan suggests the time has come to clarify the difference between a cosmetic and a drug.
The healthcare supplier has paid $56m to buy up nine generic
prescription dermatological products and four products that are
currently in development from Glades Pharmaceutical.
